Retinoblastoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：54頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Retinoblastoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Retinoblastoma - Pipeline Review, H1 2014’, provides an overview of the Retinoblastoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinoblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinoblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinoblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinoblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Retinoblastoma - Pipeline Review, H1 2014’, provides an overview of the Retinoblastoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinoblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinoblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinoblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinoblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinoblastoma Overview 6
Therapeutics Development 7
Pipeline Products for Retinoblastoma - Overview 7
Pipeline Products for Retinoblastoma - Comparative Analysis 8
Retinoblastoma - Therapeutics under Development by Companies 9
Retinoblastoma - Therapeutics under Investigation by Universities/Institutes 10
Retinoblastoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinoblastoma - Products under Development by Companies 13
Retinoblastoma - Products under Investigation by Universities/Institutes 14
Retinoblastoma - Companies Involved in Therapeutics Development 15
BioLineRx, Ltd. 15
Neotropix, Inc. 16
Cellceutix Corporation 17
Icon Bioscience, Inc. 18
RXi Pharmaceuticals Corporation 19
Retinoblastoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
NTX-010 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Kevetrin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BL-8040 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
melphalan - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Nutlin-3 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RNAi Oligonucleotide for Retinoblastoma - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Retinoblastoma - Recent Pipeline Updates 40
Retinoblastoma - Product Development Milestones 51
Featured News & Press Releases 51
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma 51
Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products under Development for Retinoblastoma, H1 2014 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Retinoblastoma - Pipeline by BioLineRx, Ltd., H1 2014 15
Retinoblastoma - Pipeline by Neotropix, Inc., H1 2014 16
Retinoblastoma - Pipeline by Cellceutix Corporation, H1 2014 17
Retinoblastoma - Pipeline by Icon Bioscience, Inc., H1 2014 18
Retinoblastoma - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Retinoblastoma Therapeutics - Recent Pipeline Updates, H1 2014 40
List of Figures
Number of Products under Development for Retinoblastoma, H1 2014 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinoblastoma Overview 6
Therapeutics Development 7
Pipeline Products for Retinoblastoma - Overview 7
Pipeline Products for Retinoblastoma - Comparative Analysis 8
Retinoblastoma - Therapeutics under Development by Companies 9
Retinoblastoma - Therapeutics under Investigation by Universities/Institutes 10
Retinoblastoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinoblastoma - Products under Development by Companies 13
Retinoblastoma - Products under Investigation by Universities/Institutes 14
Retinoblastoma - Companies Involved in Therapeutics Development 15
BioLineRx, Ltd. 15
Neotropix, Inc. 16
Cellceutix Corporation 17
Icon Bioscience, Inc. 18
RXi Pharmaceuticals Corporation 19
Retinoblastoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
NTX-010 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Kevetrin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BL-8040 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
melphalan - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Nutlin-3 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RNAi Oligonucleotide for Retinoblastoma - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Retinoblastoma - Recent Pipeline Updates 40
Retinoblastoma - Product Development Milestones 51
Featured News & Press Releases 51
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma 51
Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products under Development for Retinoblastoma, H1 2014 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Retinoblastoma - Pipeline by BioLineRx, Ltd., H1 2014 15
Retinoblastoma - Pipeline by Neotropix, Inc., H1 2014 16
Retinoblastoma - Pipeline by Cellceutix Corporation, H1 2014 17
Retinoblastoma - Pipeline by Icon Bioscience, Inc., H1 2014 18
Retinoblastoma - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Retinoblastoma Therapeutics - Recent Pipeline Updates, H1 2014 40
List of Figures
Number of Products under Development for Retinoblastoma, H1 2014 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
